NDA 215319, held by Laurus Generics Inc. Dolutegravir.
As of Nov 13, 2026, NDA 215319 (Dolutegravir), held by Laurus Generics Inc, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2023 | Original applicationNew formulation or manufacturer · Priority review | Tentative approval |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dolutegravir5MG · film;oral | Dolutegravir | Rx |
| Dolutegravir10MG · film;oral | Dolutegravir | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters